Video: New partnerships in cancer epigenetics
Our Epigenetics and Genome Stability team, led by Professor Jessica Downs, is working on a variety of research programmes that could be developed in collaboration with commercial partners.
Professor Downs’ laboratory focuses on understanding how epigenetic regulators and chromatin proteins impact on protecting the genome and the integrity of the DNA in cells, and how these are lost in cancer.
Several of its big projects revolve around the SWI/SNF chromatin remodelling complex. There are inactivating mutations in subunits of SWI/SNF in roughly 20% of cancers, and Professor Downs’ lab found that SWI/SNF is important for DNA damage responses and for the fidelity of chromosome segregation.
The team has worked in collaboration with industry partners to identify new drug targets that could take advantage of genome instabilities in tumours.
As well as continuing this work, Professor Downs’ laboratory is also looking to develop new forms of technology that will improve identification of epigenetically mis-regulated cancer samples – and would be open to new partnerships to expand in this area.
Watch more videos of our researchers
Working with pharmaceutical companies
Dr Marco Gerlinger's Translational Oncogenomics Team are keen to develop new partnerships to continue their work, and to access drugs that could reverse the resistance mechanisms that the team has identified so far.
New partnerships in cancer epigenetics
Sharing experience with industry partners
Our Molecular and Systems Oncology Team, led by Dr Paul Huang, is keen to collaborate with industry partners on a number of projects on biochemistry, computational modelling, molecular pathology and proteomics.
Collaborating with commercial partners
Our Systems and Precision Cancer Medicine team, led by Dr Anguraj Sadanandam, is investigating ways to stratify tumours based on their genetic and clinical diversity.
The benefits of partnering with industry
Our Molecular Addictions team, led by Dr Igor Vivanco, is working on a variety of projects that could be developed in collaboration with commercial partners.
Exploring new opportunities for collaborative working
Professor Uwe Oelfke, Deputy Head of the Division of Radiotherapy and Imaging, is keen to explore new opportunities for collaborative working with industry.